Drugs / TFX06
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05927779 | Apr 2023 → Dec 2024 | estrogen-receptor positive breast cancer | Zhejiang Yangli Pharmaceutical Technology Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TFX06 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05927779 ↗ |
| Route | Oral | “TFX06 tablet taken orally” NCT05927779 ↗ |